This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

TESARO Details Niraparib Phase 1 Clinical Data Presented At The 2013 ASCO Annual Meeting

  • A RECIST Response Rate of 75% Was Achieved at the 300mg Dose in Patients With Platinum-Sensitive High Grade Serous Ovarian Cancer
  • A RECIST Response Rate of 50% Was Achieved Across All Dose Levels in Patients With Platinum Sensitive Ovarian Cancer and Germline BRCA Mutations
  • Progression Free Survival Exceeded One Year Among Platinum-Sensitive Ovarian Cancer Responders, Independent of BRCA Mutation Status

CHICAGO, June 4, 2013 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, today announced that final results from a Phase 1 trial of niraparib, an inhibitor of poly ADP-ribose polymerase (PARP), were presented this morning at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago.

At a dose of 300 milligrams once daily, which represents the dose and schedule that will be utilized in the Phase 3 studies, 75% (three of four patients) with platinum sensitive high grade serous ovarian cancer (HGSOC) achieved a RECIST response. Across all dose levels (30 milligrams to 400 milligrams daily), a RECIST response rate of 46% (6/13 patients) was observed in this population. A RECIST response rate of 50% (5/10 patients) was achieved in patients with platinum sensitive ovarian cancer and germline BRCA mutations. The median duration of response was 431 days for platinum sensitive germline BRCA patients and 444 days for platinum sensitive patients who were not germline BRCA mutation carriers.

In addition, 50% (two of the four patients) with BRCA-positive breast cancer achieved a response. Of the 10 patients with prostate cancer who had evaluable circulating tumor cell count (CTC) levels, seven (70%) had a reduction of >30% in CTC count.

The ovarian cancer patients enrolled in this study had received a median of six previous regimens of systemic therapy. The breast cancer patients enrolled in this study had received a median of five previous regimens of systemic therapy.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 17,659.95 +63.60 0.36%
S&P 500 2,062.78 +5.14 0.25%
NASDAQ 4,975.9360 +17.4680 0.35%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs